GLUE vs. DCTH
GLUE (Monte Rosa Therapeutics, Inc.) and DCTH (Delcath Systems, Inc.) are both stocks. Both are in the Healthcare sector — GLUE in Biotechnology, DCTH in Medical Devices. Over the past 5 years, GLUE returned -7.59%/yr vs 3.68%/yr for DCTH. Their 0.22 correlation means their historical movements had little consistent relationship.
Performance
GLUE vs. DCTH - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GLUE achieves a 5.36% return, which is significantly lower than DCTH's 20.99% return.
GLUE
- 1D
- -27.16%
- 1M
- -31.76%
- 6M
- -19.49%
- YTD
- 5.36%
- 1Y
- 244.89%
- 3Y*
- 33.78%
- 5Y*
- -7.59%
- 10Y*
- —
- ALL TIME*
- -5.46%
DCTH
- 1D
- 1.50%
- 1M
- -7.42%
- 6M
- 23.31%
- YTD
- 20.99%
- 1Y
- 15.39%
- 3Y*
- 42.76%
- 5Y*
- 3.68%
- 10Y*
- —
- ALL TIME*
- -46.75%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $4.25M | $4.46M | $5.78M | |
| $33.43M | $32.05M | $26.85M |
GLUE vs. DCTH - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
GLUE Monte Rosa Therapeutics, Inc. | 5.36% | 125.94% | 22.83% | -25.76% | -62.73% | -7.18% |
DCTH Delcath Systems, Inc. | 20.99% | -16.11% | 189.42% | 15.56% | -53.55% | -25.91% |
Correlation
The correlation between GLUE and DCTH is 0.19, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.19 |
Correlation (3Y) Balances recent behavior with more history. | 0.22 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.21 |
Correlation (All Time) Calculated using the full available price history since Jun 24, 2021 | 0.22 |
Fundamentals
GLUE:
$1.40B
DCTH:
$421.85M
GLUE:
-$2.64
DCTH:
$0.01
GLUE:
18.97
DCTH:
7.00
GLUE:
$42.95M
DCTH:
$65.45M
GLUE:
$34.56M
DCTH:
$77.75M
GLUE:
-$139.25M
DCTH:
$222.00K
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GLUE vs. DCTH — Risk / Return Rank
GLUE
DCTH
GLUE vs. DCTH - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Monte Rosa Therapeutics, Inc. (GLUE) and Delcath Systems, Inc. (DCTH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GLUE | DCTH | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.15 | ||
| Sortino ratioReturn per unit of downside risk | +2.66 | ||
| Omega ratioGain probability vs. loss probability | 1.44 | 1.09 | +0.35 |
| Calmar ratioReturn relative to maximum drawdown | 5.62 | 0.41 | +5.22 |
| Martin ratioReturn relative to average drawdown | 12.36 | 0.83 | +11.53 |
Loading charts...
Drawdowns
GLUE vs. DCTH - Drawdown Comparison
The maximum GLUE drawdown since its inception was -94.08%, smaller than the maximum DCTH drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for GLUE and DCTH.
Loading charts...
Drawdown Indicators
| GLUE | DCTH | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.08% | -99.96% | +5.88% |
Max Drawdown (1Y)Largest decline over 1 year | -41.84% | -33.74% | -8.10% |
Max Drawdown (3Y)Largest decline over 3 years | -64.29% | -60.87% | -3.42% |
Max Drawdown (5Y)Largest decline over 5 years | -94.08% | -80.80% | -13.28% |
Current DrawdownCurrent decline from peak | -60.86% | -99.80% | +38.94% |
Average DrawdownAverage peak-to-trough decline | -73.78% | -96.47% | +22.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.05% | 16.48% | +2.57% |
Volatility
GLUE vs. DCTH - Volatility Comparison
Monte Rosa Therapeutics, Inc. (GLUE) has a higher volatility of 35.38% compared to Delcath Systems, Inc. (DCTH) at 10.23%. This indicates that GLUE's price experiences larger fluctuations and is considered to be riskier than DCTH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GLUE | DCTH | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 35.38% | 10.23% | +25.15% |
Volatility (6M)Calculated over the trailing 6-month period | 49.79% | 33.52% | +16.27% |
Volatility (1Y)Calculated over the trailing 1-year period | 97.54% | 48.02% | +49.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 101.44% | 72.50% | +28.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 100.99% | 109.21% | -8.22% |
Dividends
GLUE vs. DCTH - Dividend Comparison
Neither GLUE nor DCTH has paid dividends to shareholders.
Financials
GLUE vs. DCTH - Financials Comparison
This section allows you to compare key financial metrics between Monte Rosa Therapeutics, Inc. and Delcath Systems, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
GLUE and DCTH have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GLUE has higher volatility (35.38%) compared to DCTH (10.23%). In terms of maximum drawdown, GLUE dropped -94.08% vs DCTH's -99.96%.
GLUE currently has the higher Sharpe Ratio (2.43 vs 0.29), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GLUE and DCTH
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer